Literature DB >> 15220412

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

A Reyes-Sandoval1, J C Fitzgerald, R Grant, S Roy, Z Q Xiang, Y Li, G P Gao, J M Wilson, H C J Ertl.   

Abstract

Two triple immunization vaccine regimens with adenoviral vectors with E1 deleted expressing Gag of human immunodeficiency virus type 1 were tested for induction of T- and B-cell-mediated-immune responses in mice and in nonhuman primates. The vaccine carriers were derived from distinct serotypes of human and simian adenoviruses that fail to elicit cross-neutralizing antibodies expected to dampen the effect of booster immunizations. Both triple immunization regimens induced unprecedented frequencies of gamma interferon-producing CD8(+) T cells to Gag in mice and monkeys that remained remarkably stable over time. In addition, monkeys developed Gag-specific interleukin-2-secreting T cells, presumably belonging to the CD4(+) T-cell subset, and antibodies to both Gag and the adenoviral vaccine carriers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220412      PMCID: PMC434124          DOI: 10.1128/JVI.78.14.7392-7399.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  The critical role of CD4(+) T-cell help in immunity to HIV.

Authors:  Jonathan Luke Heeney
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

2.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

Authors:  M A Schnell; Y Zhang; J Tazelaar; G P Gao; Q C Yu; R Qian; S J Chen; A N Varnavski; C LeClair; S E Raper; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

3.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

4.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

6.  Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

Authors:  Andrei N Varnavski; Katia Schlienger; Jeffrey M Bergelson; Guang-Ping Gao; James M Wilson
Journal:  Hum Gene Ther       Date:  2003-04-10       Impact factor: 5.695

7.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

Authors:  Julie C Fitzgerald; Guang-Ping Gao; Arturo Reyes-Sandoval; George N Pavlakis; Zhi Q Xiang; Anthony P Wlazlo; Wynetta Giles-Davis; James M Wilson; Hildegund C J Ertl
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.

Authors:  Silvia Ratto-Kim; Lawrence D Loomis-Price; Naomi Aronson; Janelle Grimes; Cristin Hill; Chevelle Williams; Raphaelle El Habib; Deborah L Birx; Jerome H Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

10.  Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.

Authors:  Zhiquan Xiang; Guangping Gao; Arturo Reyes-Sandoval; Christopher J Cohen; Yan Li; Jeffrey M Bergelson; James M Wilson; Hildegund C J Ertl
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

View more
  38 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

3.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

Authors:  Nia Tatsis; Julie C Fitzgerald; Arturo Reyes-Sandoval; Kimberly C Harris-McCoy; Scott E Hensley; Dongming Zhou; Shih-Wen Lin; Ang Bian; Zhi Quan Xiang; Amaya Iparraguirre; Cesar Lopez-Camacho; E John Wherry; Hildegund C J Ertl
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

Review 4.  Viral vector vaccines make memory T cells against malaria.

Authors:  Arturo Reyes-Sandoval; John T Harty; Stephen M Todryk
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

Review 5.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

6.  Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.

Authors:  Dongming Zhou; Te-Lang Wu; Kristel L Emmer; Raj Kurupati; Steven Tuyishime; Yan Li; Wynetta Giles-Davis; Xiangyang Zhou; Zhiquan Xiang; Qin Liu; Sarah J Ratcliffe; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

7.  Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.

Authors:  Masahiko Hashimoto; Julie L Boyer; Neil R Hackett; James M Wilson; Ronald G Crystal
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.

Authors:  Anurag Sharma; Rebecca Wendland; Biin Sung; Wenzhu Wu; Thomas Grunwald; Stefan Worgall
Journal:  Vaccine       Date:  2014-08-26       Impact factor: 3.641

10.  Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.

Authors:  Soumitra Roy; Gary P Kobinger; Jianping Lin; Joanita Figueredo; Roberto Calcedo; Darwyn Kobasa; James M Wilson
Journal:  Vaccine       Date:  2007-08-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.